Literature DB >> 26617696

Overexpression of Prdx1 in hilar cholangiocarcinoma: a predictor for recurrence and prognosis.

Jie Zhou1, Weiwen Shen2, Xiaojing He3, Jing Qian2, Shiyuan Liu4, Guanzhen Yu5.   

Abstract

Prdx1 is an important member of peroxiredoxins (Prdxs) regulating various cellular signaling and differentiation. Prdx1 confers an aggressive survival phenotype of cancer cells and drug-resistance, yet its role in hilar cholangiocarcinoma is not fully investigated. In present study, we detected the expression profile of Prdx1 in 88 hilar cholangiocarcinoma by tissue arrays and immunohistochemistry. Prdx1 level was down-regulated by specific Prdx1-shRNA in vitro and the possible mechanism was investigated. Overexpression of Prdx1 was observed in 53 of 88 cases (60.2%). Prdx1 expression was significantly associated with tumor invasion, nodal metastasis, advanced disease stage. Down-regulation of Prdx1 inhibited cell proliferation and colony formation of QBC939 cells and reduced the level of SNAT1 expression. Patients with Prdx1 overexpression had a shorter disease-free survival and overall survival than those without Prdx1 expression. Multivariate analysis showed that Prdx1 was an independent prognostic factor for patients with hilar cholangiocarcinoma. The data indicate that Prdx1 may contribute to the development and progression of hilar cholangiocarcinoma, partially through regulating SNAT1 expression, and may be used as a biomarker in predicting the outcome of patients with hilar cholangiocarcinoma.

Entities:  

Keywords:  Hilar cholangiocarcinoma; Prdx1; SNAT1; prognosis; tissue microarray

Mesh:

Substances:

Year:  2015        PMID: 26617696      PMCID: PMC4637781     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  39 in total

1.  Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis.

Authors:  Mio Furuya; Jun Horiguchi; Hiroki Nakajima; Yoshikatsu Kanai; Tetsunari Oyama
Journal:  Cancer Sci       Date:  2011-12-15       Impact factor: 6.716

2.  Prognostic significance of peroxiredoxin 1 and ezrin-radixin-moesin-binding phosphoprotein 50 in cholangiocarcinoma.

Authors:  Ponlapat Yonglitthipagon; Chawalit Pairojkul; Yaovalux Chamgramol; Alex Loukas; Jason Mulvenna; Jeffrey Bethony; Vajarabhongsa Bhudhisawasdi; Banchob Sripa
Journal:  Hum Pathol       Date:  2012-03-24       Impact factor: 3.466

3.  High association of peroxiredoxins with lung cancer.

Authors:  Ylermi Soini; Vuokko L Kinnula
Journal:  Lung Cancer       Date:  2012-09-14       Impact factor: 5.705

4.  Proteomics in HepG2 hepatocarcinoma cells with stably silenced expression of PRDX1.

Authors:  Patricia Aguilar-Melero; María-José Prieto-Álamo; Juan Jurado; Arne Holmgren; Carmen Pueyo
Journal:  J Proteomics       Date:  2012-12-28       Impact factor: 4.044

5.  Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis.

Authors:  Marjo Pylväs; Ulla Puistola; Saila Kauppila; Ylermi Soini; Peeter Karihtala
Journal:  Eur J Cancer       Date:  2010-03-04       Impact factor: 9.162

6.  Overexpression of ATA1/SLC38A1 predicts future recurrence and death in Chinese patients with hilar cholangiocarcinoma.

Authors:  Wen-long Yu; Wen-ming Cong; Yongjie Zhang; Ying Chen; Fei Wang; Guanzhen Yu
Journal:  J Surg Res       Date:  2010-04-18       Impact factor: 2.192

7.  ILK and PRDX1 are prognostic markers in squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder.

Authors:  Jinghe Li; Zhu-Lin Yang; Xuebao Ren; Qiong Zou; Yuan Yuan; Lufeng Liang; Meigui Chen; Senlin Chen
Journal:  Tumour Biol       Date:  2012-10-13

8.  Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress.

Authors:  H C Whitaker; D Patel; W J Howat; A Y Warren; J D Kay; T Sangan; J C Marioni; J Mitchell; S Aldridge; H J Luxton; C Massie; A G Lynch; D E Neal
Journal:  Br J Cancer       Date:  2013-07-23       Impact factor: 7.640

9.  Peroxiredoxin 1 is a tumor-associated antigen in esophageal squamous cell carcinoma.

Authors:  Pengfei Ren; Hua Ye; Liping Dai; Mei Liu; Xinxin Liu; Yurong Chai; Qing Shao; Yang Li; Ningjing Lei; Bo Peng; Wu Yao; Jianying Zhang
Journal:  Oncol Rep       Date:  2013-09-04       Impact factor: 3.906

10.  Activation of SNAT1/SLC38A1 in human breast cancer: correlation with p-Akt overexpression.

Authors:  Kuo Wang; Fang Cao; Wenzheng Fang; Yongwei Hu; Ying Chen; Houzhong Ding; Guanzhen Yu
Journal:  BMC Cancer       Date:  2013-07-12       Impact factor: 4.430

View more
  9 in total

Review 1.  Mitochondria-Centric Review of Polyphenol Bioactivity in Cancer Models.

Authors:  Jan F Stevens; Johana S Revel; Claudia S Maier
Journal:  Antioxid Redox Signal       Date:  2017-12-11       Impact factor: 8.401

2.  Membrane Bound Peroxiredoxin-1 Serves as a Biomarker for In Vivo Detection of Sessile Serrated Adenomas.

Authors:  Sangeeta Jaiswal; Bishnu Joshi; Jing Chen; Fa Wang; Michael K Dame; Jason R Spence; Gina M Newsome; Erica L Katz; Yatrik M Shah; Sadeesh K Ramakrishnan; Gaoming Li; Miki Lee; Henry D Appelman; Rork Kuick; Thomas D Wang
Journal:  Antioxid Redox Signal       Date:  2021-12-21       Impact factor: 8.401

3.  Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study.

Authors:  Lianghe Jiao; Jing Wei; Jun Ye; Chuanmeng Zhang
Journal:  Dis Markers       Date:  2021-03-03       Impact factor: 3.434

4.  Peroxiredoxin 1 expression in active ulcerative colitis mucosa identified by proteome analysis and involvement of thioredoxin based on immunohistochemistry.

Authors:  Kayo Horie; Tetuo Mikami; Tsutomu Yoshida; Yuichi Sato; Isao Okayasu
Journal:  Oncol Lett       Date:  2017-12-08       Impact factor: 2.967

5.  A Peroxidase Peroxiredoxin 1-Specific Redox Regulation of the Novel FOXO3 microRNA Target let-7.

Authors:  Barbara L Hopkins; Monica Nadler; John J Skoko; Thierry Bertomeu; Andrea Pelosi; Parisa Mousavi Shafaei; Kevin Levine; Anja Schempf; Bodvael Pennarun; Bo Yang; Dipak Datta; Octavian Bucur; Kenneth Ndebele; Steffi Oesterreich; Da Yang; Maria Giulia Rizzo; Roya Khosravi-Far; Carola A Neumann
Journal:  Antioxid Redox Signal       Date:  2017-05-01       Impact factor: 8.401

6.  The role of peroxiredoxins in cancer.

Authors:  Arianna Nicolussi; Sonia D'Inzeo; Carlo Capalbo; Giuseppe Giannini; Anna Coppa
Journal:  Mol Clin Oncol       Date:  2017-01-10

Review 7.  Peroxiredoxin 1 - an antioxidant enzyme in cancer.

Authors:  Chenbo Ding; Xiaobo Fan; Guoqiu Wu
Journal:  J Cell Mol Med       Date:  2016-09-21       Impact factor: 5.310

8.  The Role of Redox-Regulating Enzymes in Inoperable Breast Cancers Treated with Neoadjuvant Chemotherapy.

Authors:  Nelli Roininen; Kirsi-Maria Haapasaari; Peeter Karihtala
Journal:  Oxid Med Cell Longev       Date:  2017-11-19       Impact factor: 6.543

9.  The prognostic values of the peroxiredoxins family in ovarian cancer.

Authors:  Saisai Li; Xiaoli Hu; Miaomiao Ye; Xueqiong Zhu
Journal:  Biosci Rep       Date:  2018-09-05       Impact factor: 3.840

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.